Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

17. Mai 2011 16:30 ET | Quelle: BioLineRx Ltd.

BioLineRx Acquires Exclusive License Rights From Algen for Cancer Therapeutic BL-7030

JERUSALEM, May 17, 2011 (GLOBE NEWSWIRE) -- BioLineRx (TASE:BLRX) announced today that it has acquired the rights to compound BL-7030, a novel molecule for targeted cancer therapy, from Algen, which...
11. Mai 2011 07:03 ET | Quelle: BioLineRx Ltd.

BioLineRx Reacquires Rights to Leading Schizophrenia Drug Candidate BL-1020

JERUSALEM, May 11, 2011 (GLOBE NEWSWIRE) -- BioLineRx Ltd. (TASE:BLRX), a biopharmaceutical development company dedicated to building a portfolio of products for unmet medical needs or with advantages...
04. April 2011 14:58 ET | Quelle: BioLineRx Ltd.

BioLineRx Receives Notice of Allowance From USPTO for Patent Covering BL-1020 Drug for Treatment of Schizophrenia

JERUSALEM, April 4, 2011 (GLOBE NEWSWIRE) -- BioLineRx (TASE:BLRX) announced today that a Notice of Allowance has been issued by the United States Patent and Trademark Office (USPTO) for a patent...